ホーム › 非小細胞肺癌 › ペンシルベニア › Philadelphia
Philadelphia、PAにおける非小細胞肺癌の臨床試験
Philadelphiaとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する51件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
- 他5件
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #98, Philadelphia
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
被験者募集中第3相
- Perelman Center for Advanced Medicine ( Site 3205), Philadelphia
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Lankenau Medical Center, Wynnewood · 7マイル先
- 他2件
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Alliance Cancer Specialists, PC, Wynnewood · 7マイル先
- Consultants in Medical Oncology and Hematology, P.C., Broomall · 10マイル先
- Alliance Cancer Specialists, PC, Media · 12マイル先
- 他1件
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
被験者募集中第3相
- Alliance Cancer Specialists - Media, Media · 12マイル先
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Philadelphia
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- University of Pennsylvania, Philadelphia
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Health Northeast, Philadelphia
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Philadelphia
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
被験者募集中第2相
- Lankenau Medical Center, Wynnewood · 7マイル先
- Riddle Memorial Hospital, Media · 12マイル先
- Paoli Memorial Hospital, Paoli · 18マイル先
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- Local Institution - 0504, Philadelphia
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
被験者募集中観察研究
- Lankenau Medical Center, Paoli · 18マイル先
An External Control Arm Study in Non-Small Cell Lung Cancer
被験者募集中観察研究
- Main Line Health, Wynnewood · 7マイル先
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- Hospital of the University of Pennsylvania, Philadelphia
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Philadelphia
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- University of Pennsylvania, Philadelphia
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- USO - Alliance Cancer Specialists, PC, Horsham · 16マイル先
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
被験者募集中第3相
- Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
被験者募集中第1/2相
- Thomas Jefferson University Research Facility, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
被験者募集中第1相
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
被験者募集中第1相
- Thomas Jefferson University, Philadelphia
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- Fox Chase Cancer Center, Philadelphia
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
被験者募集中観察研究
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
被験者募集中第1/2相
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
被験者募集中第2相
- Abramson Cancer Center ( Site 0010), Philadelphia
TCR1188-ABC Cells in KRAS-mutated Cancers
被験者募集中第1相
- University of Pennsylvania, Philadelphia
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
被験者募集中第1/2相
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Thomas Jefferson University, Philadelphia
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
被験者募集中第1相
- Jefferson University Hospitals, Philadelphia
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
被験者募集中第1/2相
- Fox Chase Cancer Center, Philadelphia
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- Thomas Jefferson University Hospital, Philadelphia
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- Abramson Cancer Center, Philadelphia
MOv19-BBz CAR T Cells in FRa+ Cancers
被験者募集中第1相
- University of Pennsylvania, Philadelphia
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
被験者募集中第2相
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- Perelman Center for Advanced Medicine /ID# 250188, Philadelphia
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8マイル先
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
被験者募集中第2相
- Fox Chase Cancer Center, Philadelphia
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8マイル先
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
被験者募集中第2相
- Fox Chase Cancer Center, Philadelphia
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
被験者募集中第2相
- University of Pennsylvania, Philadelphia
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Fox Chase Cancer Center, Philadelphia
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
被験者募集中第1/2相
- University of Pennsylvania, Philadelphia
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pennsylvania, Philadelphia
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
被験者募集中
- Jefferson Health Northeast, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Abington Memorial Hospital, Abington · 12マイル先
- 他1件
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
被験者募集中第1/2相
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Philadelphia
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Philadelphiaにおける他の研究
- がん（全種類）59件の研究
- 乳がん56件の研究
- 転移性癌46件の研究
- 前立腺がん44件の研究
- 大腸癌44件の研究
- 卵巣がん44件の研究
- 肺がん36件の研究
- 急性骨髄性白血病34件の研究
- 心不全31件の研究
- 子宮内膜がん28件の研究
- うつ病26件の研究
- 膵臓がん26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。